LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lakewood-Amedex Biotherapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.58+0.00 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $828.29K
- P/E (TTM)
- –
- Dividend yield
- –
Lakewood-Amedex Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lakewood-Amedex Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $1.38M | $197.05M |
| Enterprise Value | -$3.20M | $106.56M |
| PB Ratio | 0.32 | 2.14 |
| P/TBV Ratio | 0.32 | 2.46 |
Balance sheet
| Measure | Lakewood-Amedex Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.58M | $62.42M |
| Net Cash (Debt) | $4.58M | $15.68M |
| Net Cash Per Share | $1.93 | $0.65 |
| Equity (Book Value) | $4.33M | $48.79M |
| Book Value Per Share | $1.83 | $1.36 |
| Tangible Book Value | $4.33M | $23.06M |
| Working Capital | $4.22M | $75.77M |
Financial position
| Measure | Lakewood-Amedex Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.70 | 3.30 |
| Quick Ratio | 7.29 | 2.39 |
Shares
| Measure | Lakewood-Amedex Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 2,369,690 | 59,128,900 |
| Shares Change (QoQ) | -69.2% | 0.54% |
| Shares Held by Institutions | 4.13% | 59.4% |
Scores
| Measure | Lakewood-Amedex Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -17.04 | 0.10 |
Calculated by StockData from Lakewood-Amedex Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.